Fundz

Who to call at Debiopharm, and when

Fundz watches for the moments Debiopharm starts buying, and tells you who to reach.

  • An alert the day Debiopharm raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Debiopharm, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Debiopharm. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs

Sep 12, 2024

Contract Type

agreement

LausanneBiotechnologyHealth CareTherapeutics

Description

ITM Isotope Technologies Munich SE (ITM) and Debiopharm have entered an agreement under which ITM gains the exclusive global license for the clinical and commercial development of the peptide-based, theranostic pair ITM-91/ITM-94D, targeting the Carbonic Anhydrase IX (CA IX) surface protein.

Quick answer

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs (September 12, 2024). Debiopharm is based in Lausanne, Vaud, Switzerland.

What agreement did Debiopharm announce on September 12, 2024?
ITM Isotope Technologies Munich SE (ITM) and Debiopharm have entered an agreement under which ITM gains the exclusive global license for the clinical and commercial development of the peptide-based, theranostic pair ITM-91/ITM-94D, targeting the Carbonic Anhydrase IX (CA IX) surface protein.
What does Debiopharm do?
Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases.
Where is Debiopharm based?
Debiopharm is based in Lausanne, Vaud, Switzerland.

Source: Fundz verified event record.

Company Information

Company

Debiopharm

Location

Lausanne, Vaud, Switzerland

About

Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.

Related People

Angela
Likely contact at this company
••••••••@••••••••

See Angela's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Debiopharm's next move

Learn about Strategic plan

Debiopharm signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.